FDA expands Enhertu approval to include HER2-ultralow breast cancer patients
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.DN-d7ZPu.js ...
来自MSN16 小时
Skincare Dos and Don’ts: 7 ingredients you should never mix
Did you know that some skincare ingredients simply don’t mix well together? When it comes to skincare, finding the right ...
PoliticsHome19 小时
HM chief inspector of prisons: 'If someone were to get a gun into a prison, all bets are off'
Speaking to Sienna Rodgers, HM chief inspector of prisons Charlie Taylor details the many failures he has seen across the ...
It’s judgment day for Bob Menendez
A federal judge will sentence former Sen. Bob Menendez on Wednesday for selling his office — an extraordinary fall even for a ...
Soap Central on MSN6 小时
The Young and the Restless: Genoa City's Rogues Gallery
Let's dive into the top 5 villains and villainesses and what makes them have a case to be known as the best of the worst on ...
Danaher Corporation (DHR) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Conference Call January 29, 2025 8:00 AM ETCompany ParticipantsJohn Bedford - VP of IRRainer Blair ...
clinicaladvisor.com14 小时
Enhertu Approved for HR+, HER2-Low/Ultralow Metastatic Breast Cancer
Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...